A bimodal bioactive glass wound dressing and dry milling-airflow coupling preparation method and application thereof

Abstract

This invention belongs to the technical field of medical wound repair materials, specifically relating to a bimodal bioactive glass wound dressing and its dry grinding-airflow coupling preparation method and application. The core raw material of the wound dressing is 45S5 bioactive glass powder, which is a pure system without added antibacterial agents or modifiers. The mass percentage composition of the 45S5 bioactive glass is: SiO2 45%, Na2O2 4.5%, CaO2 4.5%, P2O5 6%. The 45S5 bioactive glass powder exhibits a bimodal particle size distribution of 5-10 μm, wherein the powder with a particle size of 5-7 μm accounts for 60%-70% by mass, and the powder with a particle size of 7-10 μm accounts for 30%-40% by mass. It is used to form a breathable protective layer on the wound surface; the powder is uniformly dispersed and does not agglomerate. This invention has significant beneficial effects: the specific bimodal particle size design produces a significant physical synergistic effect, achieving an optimal balance in wound adhesion and breathability. The process ensures batch-to-batch stability of the dual-modal structure. The pure system formulation achieves non-irritating antibacterial and anti-inflammatory effects.

Description

Technical Field

[0001] This invention belongs to the field of medical wound repair materials technology, specifically relating to a wound dressing with 45S5 bioactive glass as the core raw material, which achieves precise diameter control through a dry grinding-airflow coupling process. It is a dual-modal bioactive glass wound dressing specifically for minimally invasive cosmetic procedures (laser, photon skin rejuvenation, microdermabrasion, chemical peels, etc.) and its preparation method. In particular, it relates to a dual-modal bioactive glass wound dressing and its dry grinding-airflow coupling preparation method and application. Background Technology

[0002] With the rapid development of the medical aesthetics industry, minimally invasive medical aesthetic procedures such as laser treatments, photofacial rejuvenation, microdermabrasion, and chemical peels are widely used in areas such as skin whitening, anti-aging, and acne treatment due to their advantages of minimal trauma, rapid recovery, and significant results. However, these minimally invasive procedures can create tiny wounds on the skin's epidermis, damaging the skin barrier and easily leading to problems such as redness, stinging, infection, and slow healing. Therefore, specialized wound repair dressings are needed for intervention.

[0003] Currently, there are many types of medical wound dressings, among which bioactive glass is widely used in wound repair due to its excellent biocompatibility, osteoconductivity, and antibacterial and healing-promoting abilities. 45S5 bioactive glass, as a classic bioactive glass system, possesses excellent bioactivity due to its chemical composition (SiO2, Na2O, CaO, P2O5), and can release Ca... 2+ Si 4+ Plasma promotes cell proliferation and differentiation, and accelerates wound healing.

[0004] However, existing bioactive glass powders (such as those published in CN1325291A and CN1569246A) primarily focus on the ion release characteristics of the material itself, neglecting the adaptability of the powder's physical morphology (especially its microscopic particle size distribution) to the specific microenvironment of small wounds. Specifically, wound dressings made from 45S5 bioactive glass still face the following technical bottlenecks in minimally invasive aesthetic medicine settings: (1) Particle size distribution is difficult to balance "filling" and "protection": Most existing powders have a single-peak distribution or a broad gradient distribution (such as less than 100μm or less than 20μm). Although particles with too small a size (≤5μm) are easy to disperse, they are difficult to form an effective breathable protective layer on the wound surface; although particles with a larger size (>10μm) can form a protective layer, they are slow to fill small wounds and are easy to agglomerate, affecting the adhesion.

[0005] (2) Existing processes cannot reliably achieve precise narrow-distribution dual-mode: conventional single ball milling easily leads to powder agglomeration and uneven distribution; while conventional air jet milling is difficult to precisely control the specific ratio of dual-mode particle size structure. The lack of stable process support results in large batch-to-batch differences in powder and poor dispersibility, which in turn affects the final bioactivity and repair effect.

[0006] (3) Risk of irritation to sensitive wounds: Most dressings add chemical antibacterial agents or chemically modify 45S5 to enhance antibacterial effects, which can easily cause secondary irritation to sensitive skin with damaged barrier after minimally invasive surgery. Summary of the Invention

[0007] The purpose of this invention is to address the problems of unreasonable particle size distribution and difficulty in stable particle size control in the preparation process of bioactive glass powders in existing technologies. This invention provides a dual-modal bioactive glass wound dressing specifically for minimally invasive medical aesthetic procedures, along with its dry grinding-airflow coupling preparation method and application. The invention aims to provide a pure powder dressing system more suitable for sensitive small wounds, maintaining low irritation while simultaneously ensuring rapid wound filling, surface breathability and protection, powder dispersibility, and batch-to-batch particle size stability.

[0008] To achieve the above objectives, this invention provides a bimodal bioactive glass wound dressing. The core raw material of the wound dressing is 45S5 bioactive glass powder, which is a pure system without added antibacterial agents or modifiers. The mass percentage composition of the 45S5 bioactive glass is: SiO2 45%, Na2O2 4.5%, CaO2 4.5%, P2O5 6%. The 45S5 bioactive glass powder exhibits a bimodal particle size distribution of 5-10 μm, wherein the powder with a particle size of 5-7 μm accounts for 60%-70% by mass, and the powder with a particle size of 7-10 μm accounts for 30%-40% by mass. It is used to form a breathable protective layer on the wound surface; the powder is uniformly dispersed and free from agglomeration.

[0009] In the 45S5 bioactive glass powder, the powder with a particle size of 5-7μm accounts for 65% of the mass, and the powder with a particle size of 7-10μm accounts for 35% of the mass.

[0010] The wound dressing also includes a compound solvent, which is physiological saline or hyaluronic acid, and the mass ratio of the 45S5 bioactive glass powder to the compound solvent is 15-25:75-85.

[0011] The mass ratio of the 45S5 bioactive glass powder to the compound solvent is 20:80.

[0012] The present invention also provides a dual-modal bioactive glass wound dressing as described in any of the above claims and its dry grinding-airflow coupling preparation method, comprising the following steps: (1) Precursor preparation: weigh SiO2, Na2O, CaO, and P2O5 raw materials by mass percentage and mix them evenly, melt them at 1200-1300℃ for 2-3 hours, cool them to room temperature after melting, and crush them to obtain block precursors; (2) Dry grinding and coarse crushing: place the block precursors in a zirconia ball mill for anhydrous dry grinding, control the ball-to-material mass ratio to be 10:1-15:1, the rotation speed to be 300-400 r / min, dry grind for 2-4 hours to obtain primary powder; (3) Dual-modal airflow pulverization: feed the primary powders into a closed-loop airflow pulverizer, control the pulverization pressure to be 0.6-0.8 MPa, and the classifier rotation speed to be 1500-2500. r / min, combined with online particle size monitoring to adjust parameters in real time, to prepare powder with the 5-10μm dual-modal particle size distribution; (4) Multi-stage negative pressure sieving: the powder obtained in step (3) is sequentially sieved through 100 mesh and 200 mesh sieves under negative pressure, and the finished 45S5 bioactive glass powder is collected.

[0013] In step (1), the melting temperature is 1250℃ and the melting time is 2.5h.

[0014] In step (2), the conditions for dry grinding and coarse crushing are: ball-to-material mass ratio of 12:1, rotation speed of 350 r / min, and dry grinding time of 3h.

[0015] In step (3), the conditions for the dual-mode airflow pulverization are: pulverization pressure of 0.7 MPa and classifier speed of 2000 r / min.

[0016] The present invention also provides the application of the bimodal bioactive glass wound dressing described in any of the above claims in the preparation of wound repair products for minimally invasive medical aesthetic procedures.

[0017] The minimally invasive medical aesthetic procedures mentioned include those following laser treatments, photon skin rejuvenation, microdermabrasion, or chemical peels; the wound repair products are compatible with procedures including topical application, electrotherapy, needle-free mesotherapy, microneedling, or mesotherapy machine injection.

[0018] Compared with the prior art, the present invention has the following significant advantages: 1. The specific dual-modal particle size design produces a significant physical synergistic effect. This invention abandons the conventional single-peak or broad particle size range, limiting a strict dual-modal structure of 5-7 μm (60%-70%) and 7-10 μm (30%-40%). At this specific ratio, the smaller 5-7 μm particle size powder can quickly sink and fill the small wounds created by minimally invasive medical aesthetic procedures, while the larger 7-10 μm particle size powder supports each other on the surface, forming a protective layer with excellent breathability. This particle size combination effectively avoids the problems of easy agglomeration of single-peak small particle size and insufficient adhesion of single-peak large particle size, achieving an optimal balance in wound adhesion, breathability, and ion release curves.

[0019] 2. The dry grinding-airflow coupling process ensures batch-to-batch stability of the dual-modal structure. The method of this invention is not a simple superposition of conventional pulverization methods. By providing a suitable feed particle size through dry grinding coarse crushing, and then using closed-loop airflow pulverization, online particle size monitoring feedback, and negative pressure sieving, the agglomeration phenomenon that is very easy to occur when preparing extremely small glass powders in existing technologies is overcome. It can accurately and stably retain and produce the above-mentioned dual-modal particle size in proportion, ensuring the uniformity of product dispersion and stable bioactivity.

[0020] 3. The pure system formulation achieves non-irritating antibacterial and anti-inflammatory effects. Based on the high specific surface area and excellent dispersibility imparted by the dual-modal particle size, the powder of this invention can release Ca to a very full extent. 2+ Si 4+ Ions. Without any chemical modification or added antibacterial agents, it can achieve an antibacterial rate of ≥98% and a mite inhibition rate of ≥94%, fundamentally eliminating the secondary irritation of the skin barrier caused by additives, and is extremely suitable for sensitive skin after minimally invasive medical aesthetic procedures. Attached Figure Description

[0021] Figure 1 This is a flowchart of the dry grinding-airflow coupling preparation method of the bimodal bioactive glass wound dressing of this application; Figure 2 This is an optical schematic diagram of the bimodal bioactive glass powder prepared in Examples 1-3 of this application. Detailed Implementation

[0022] The present invention will be further described in detail below with reference to specific embodiments.

[0023] In the following examples and comparative examples, all raw materials used were commercially available conventional raw materials. The purity of silicon dioxide (SiO2), sodium oxide (Na2O), calcium oxide (CaO), and phosphorus pentoxide (P2O5) was ≥99.5%. The zirconia ball mill, closed-loop airflow pulverizer, online particle size analyzer, and negative pressure sieve were all commercially available conventional equipment. The performance testing methods are as follows: (1) Particle size distribution test: The particle size distribution of the powder was measured using a laser particle size analyzer, and the proportion of particles with a diameter of 5-7μm and 7-10μm was recorded; (2) Antibacterial performance test: The antibacterial rate of the dressing was determined by using the agar diffusion method with Staphylococcus aureus and Escherichia coli as test strains; (3) Mite-inhibiting performance test: The mite-inhibiting rate of the dressing was determined by using the slide method with dust mites as the test object; (4) Anti-inflammatory performance test: By establishing a mouse skin inflammation model, observe the reduction of redness and swelling at the inflamed site after dressing treatment, and score (0-4 points, the lower the score, the better the anti-inflammatory effect). (5) Healing performance test: By establishing a mouse skin minimally invasive wound model, the wound healing time was recorded and the healing rate was calculated; (6) Irritation test: The skin irritation test was used to observe the reaction of rabbit skin after the dressing was applied and to evaluate the irritation (no irritation, mild irritation, moderate irritation, severe irritation).

[0024] Example 1

[0025] This embodiment provides a bimodal bioactive glass wound dressing specifically for minimally invasive medical aesthetic procedures and its preparation method. The specific steps are as follows: (1) Preparation of precursor: Weigh 45g of SiO2, 24.5g of Na2O, 24.5g of CaO and 6g of P2O according to the mass ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O 56%, mix them evenly and put them into a high temperature furnace, melt at 1250℃ for 2.5h, cool and crush them into block precursors; (2) Dry grinding and coarse crushing: The block precursor is put into a zirconia ball mill with a ball-to-material ratio of 12:1 and a rotation speed of 350 r / min. It is then dry ground for 3 hours without water to obtain primary powder. (3) Dual-mode airflow milling: The primary powder is fed into a closed-loop airflow mill with a milling pressure of 0.7 MPa and a classifier speed of 2000 r / min. The parameters are adjusted by online particle size monitoring to obtain dual-mode powder. (4) Multi-stage negative pressure screening: The dual-mode powder is passed through 100-mesh and 200-mesh sieves in sequence to remove impurities and unqualified particles; (5) Storage and compounding of finished products: Store in a sterile and sealed container. When using, compound the powder with saline solution at a ratio of 20:80 and apply it to the epidermis after laser treatment.

[0026] Tests showed that the particle size distribution of the powder prepared in this embodiment was 65% 5-7 μm and 35% 7-10 μm, with uniform dispersion and no agglomeration; the test results of various performances are shown in Table 1.

[0027] Example 2

[0028] This embodiment provides a bimodal bioactive glass wound dressing specifically for minimally invasive medical aesthetic procedures and its preparation method. The specific steps are as follows: (1) Preparation of precursor: Weigh 90g of SiO2, 49g of Na2O, 49g of CaO and 12g of P2O5 according to the mass ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O5 6%, mix them evenly and put them into a high temperature furnace, melt them at 1200℃ for 3h, cool them and crush them into block precursors; (2) Dry grinding and coarse crushing: The block precursor is put into a zirconia ball mill with a ball-to-material ratio of 10:1 and a rotation speed of 300 r / min. It is then dry ground for 4 hours without water to obtain primary powder. (3) Dual-mode airflow milling: The primary powder is fed into a closed-loop airflow mill with a milling pressure of 0.6 MPa and a classifier speed of 1500 r / min. The parameters are adjusted by online particle size monitoring to obtain dual-mode powder. (4) Multi-stage negative pressure screening: The dual-mode powder is passed through 100-mesh and 200-mesh sieves in sequence to remove impurities and unqualified particles; (5) Storage and compounding of finished products: Store in a sterile and sealed container. When using, compound the powder with hyaluronic acid at a ratio of 15:85 for electro-ionization after phototherapy.

[0029] Tests showed that the powder prepared in this embodiment had a particle size distribution of 70% 5-7 μm and 30% 7-10 μm, and was uniformly dispersed without agglomeration; the test results of various performances are shown in Table 1.

[0030] Example 3

[0031] This embodiment provides a bimodal bioactive glass wound dressing specifically for minimally invasive medical aesthetic procedures and its preparation method. The specific steps are as follows: (1) Preparation of precursor: Weigh 135g of SiO2, 73.5g of Na2O, 73.5g of CaO and 18g of P2O5 according to the mass ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O5 6%, mix them evenly and put them into a high temperature furnace, melt them at 1300℃ for 2h, cool them and crush them into block precursors; (2) Dry grinding and coarse crushing: The block precursor is put into a zirconia ball mill with a ball-to-material ratio of 15:1 and a rotation speed of 400 r / min. It is then dry ground for 2 hours without water to obtain primary powder. (3) Dual-mode airflow milling: The primary powder is fed into a closed-loop airflow mill with a milling pressure of 0.8 MPa and a classifier speed of 2500 r / min. The parameters are adjusted by online particle size monitoring to obtain dual-mode powder. (4) Multi-stage negative pressure screening: The dual-mode powder is passed through 100-mesh and 200-mesh sieves in sequence to remove impurities and unqualified particles; (5) Storage and compounding of finished products: Store in a sterile and sealed container. When using, compound the powder with saline solution at a ratio of 25:75 for use as a needle roller after microdermabrasion.

[0032] Tests showed that the particle size distribution of the powder prepared in this embodiment was 60% 5-7 μm and 40% 7-10 μm, with uniform dispersion and no agglomeration; the test results of various performances are shown in Table 1.

[0033] Comparative Example 1 This comparative example provides a conventional bioactive glass wound dressing and its preparation method, to compare the advantages of the present invention. The specific steps are as follows: (1) Preparation of precursor: Weigh the raw materials according to the mass ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O 56%, mix them evenly, melt them at 1250℃ for 2.5h, and then cool and crush them. (2) Single ball milling: The block precursor is put into a zirconia ball mill with a ball-to-material ratio of 12:1, a rotation speed of 350 r / min, and dry milling for 3 hours without water to obtain single-peak particle size powder (particle size 3-5 μm). (3) Sieving and storage: Pass through a 200-mesh sieve, store in a sterile and sealed container, and mix with the powder at a ratio of 20:80 for use as a topical application after laser treatment.

[0034] Tests showed that the powder prepared in this comparative example had a single-peak particle size (3-5 μm) and slight agglomeration; the test results of various properties are shown in Table 1.

[0035] Comparative Example 2 This comparative example provides a conventional bioactive glass wound dressing and its preparation method, to compare the advantages of the present invention. The specific steps are as follows: (1) Preparation of precursor: Weigh the raw materials according to the molar ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O 56%, mix them evenly, melt them at 1250℃ for 2.5h, and then cool and crush them. (2) Graded and sorted preparation: The block precursor was placed in a zirconia ball mill with a ball-to-material ratio of 12:1 and a rotation speed of 350 r / min. It was dry-milled for 3 hours without water. Then, a closed-loop airflow pulverizer was used for precise graded screening to remove coarse particles larger than 7 μm, resulting in single-peak particle size powder (particle size 5–7 μm). (3) Sieving and storage: Pass through 100 mesh and 200 mesh sieves in sequence, store in a sterile and sealed container, and mix with the powder and saline solution at a ratio of 20:80 for application to the epidermis after laser treatment.

[0036] Tests showed that the powder prepared in this comparative example had a single-peak particle size (5–7 μm), and the powder was free of agglomeration and uniformly dispersed; the test results of various properties are shown in Table 1.

[0037] Comparative Example 3 This comparative example provides a conventional bioactive glass wound dressing and its preparation method, to compare the advantages of the present invention. The specific steps are as follows: (1) Preparation of precursor: Weigh the raw materials according to the molar ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O 56%, mix them evenly, melt them at 1250℃ for 2.5h, and then cool and crush them. (2) Graded and sorted preparation: The block precursor was placed in a zirconia ball mill with a ball-to-material ratio of 12:1 and a rotation speed of 350 r / min. It was dry-milled for 3 hours without water. Then, a closed-loop airflow pulverizer was used for precise graded screening to remove fine particles below 7 μm, resulting in single-peak particle size powder (particle size 7–10 μm). (3) Sieving and storage: Pass through 100 mesh and 200 mesh sieves in sequence, store in a sterile and sealed container, and mix with the powder and saline solution at a ratio of 20:80 for application to the epidermis after laser treatment.

[0038] Tests showed that the powder prepared in this comparative example had a single-peak particle size (7–10 μm), and the powder was free of agglomeration and uniformly dispersed; the test results of various properties are shown in Table 1.

[0039] Comparative Example 4 This comparative example provides a conventional bioactive glass wound dressing and its preparation method, simulating existing publicly available prior art to highlight the advantages of this invention. The specific steps are as follows: (1) Preparation of precursor: Weigh the raw materials according to the molar ratio of SiO2 45%, Na2O 24.5%, CaO 24.5% and P2O 56%, mix them evenly, melt them at 1250℃ for 2.5h, and then cool and crush them. (2) Conventional crushing and grinding: The block precursor is subjected to free crushing combined with simple ball milling, with a ball-to-material ratio of 12:1, a rotation speed of 350 r / min, and dry grinding for 3 hours without water. There is no airflow for precise classification and no particle size ratio control, resulting in 2–10 μm disordered wide distribution powder. (3) Sieving and storage: Simply sieve through 200 mesh, store in a sterile and sealed container, and mix powder and saline at a ratio of 20:80 for application to the epidermis after laser treatment.

[0040] Tests showed that the powder prepared in this comparative example had a disordered wide distribution of 2–10 μm and slight agglomeration; the test results of various properties are shown in Table 1.

[0041] Table 1 Performance test results of Examples 1-3 and Comparative Example 1

[0042] Examples 1-3 all achieved a dual-modal particle size distribution of 5-10 μm, with uniform powder dispersion and no agglomeration. This is attributed to the dry grinding-airflow coupling process used in this invention, combined with online particle size monitoring and multi-stage negative pressure sieving, which effectively solved the problems of powder agglomeration and uneven particle size distribution. In contrast, Comparative Example 1, using a single ball milling process, only obtained powder with a single peak particle size of 3-5 μm, and slight agglomeration was present. Comparative Examples 2 and 3, using airflow classification to prepare powder with a single particle size, although exhibiting good dispersion and no agglomeration, only yielded homogeneous single-peak powder of 5-7 μm and 7-10 μm, with a single particle size structure. Comparative Example 4 simulated the preparation process in the existing publicly available prior art, using conventional crushing combined with simple ball milling, without precise classification control, resulting in powder with a disordered wide distribution of 2-10 μm, exhibiting local agglomeration and mixed particle size. This demonstrates that relying solely on a single crushing process cannot achieve precise particle size control, and conventional non-classification preparation methods are also difficult to guarantee the uniformity of powder particle size and structural stability.

[0043] Examples 1-3 all exhibited antibacterial rates ≥98.5% and mite inhibition rates ≥94.1%, significantly higher than all comparative examples. This is because the dual-mode particle size powder of the present invention has a larger specific surface area, enabling more complete release of Ca. 2+ Si 4+ Ions exert their own antibacterial and anti-mite effects; however, the single-peak small-particle powder in Comparative Example 1 is prone to agglomeration, resulting in insufficient ion release; the pure fine-particle powder in Comparative Example 2 has loose packing and a simple structure, resulting in short ion retention time; the pure coarse-particle powder in Comparative Example 3 has a small effective specific surface area when in contact with the wound, resulting in low ion action efficiency; and the wide-distribution powder in Comparative Example 4 has disordered particle size stacking, resulting in large fluctuations in ion release. None of the above four types of powders can achieve excellent and stable antibacterial and anti-mite effects.

[0044] The anti-inflammatory scores of Examples 1-3 were all ≤1.0, and the wound healing time was all ≤5.5 days, which were significantly better than the comparative examples. This is because the dual-mode particle size powder can not only quickly fill the wound, but also form a breathable protective layer to reduce external stimuli. At the same time, the released ions can effectively inhibit the inflammatory response, promote cell proliferation, and accelerate wound healing. In contrast, the single-peak powder has inherent structural defects. Fine-particle powder has weak film-forming protective ability, coarse-particle powder has poor wound adhesion and filling, and wide-distribution powder has discontinuities in protection and is prone to repeated inflammation. Ultimately, this led to slow inflammation resolution and prolonged wound healing period in the comparative examples. Regarding skin irritation, Examples 1-3 showed no irritation and were suitable for sensitive wounds in cosmetic procedures. Comparative Examples 2 and 3, while containing single-peak powders without chemical irritation, exhibited poor functional compatibility. Comparative Examples 1 and 4 showed slight irritation, partly due to the tendency of single-peak ultrafine powders and widely distributed mixed powders to agglomerate, resulting in excessively high local powder concentrations; and partly due to the poor powder uniformity produced by conventional preparation processes, which could easily cause physical friction irritation to damaged and sensitive wounds. In summary, the 5-10μm precise dual-modal powder prepared by the dry grinding-airflow coupling process of this invention differs from the single-peak powders and disordered widely distributed powders in existing technologies. The coarse and fine particles produce a synergistic effect, and all performance indicators are superior to all comparative examples, resulting in unexpected technical effects.

[0045] In addition, there are slight differences in performance among Examples 1 to 3. Among them, Example 1 (preferred parameters) has the best overall performance, indicating that the optimized process parameters and particle size ratio can further improve the repair effect of the dressing. Although the parameters of Examples 2 and 3 are slightly different, they can both meet the repair needs of minimally invasive medical aesthetic wounds, demonstrating the flexibility and stability of the process of the present invention.

[0046] The bimodal bioactive glass wound dressing provided by this invention, specifically designed for minimally invasive cosmetic procedures, features a 5-10μm bimodal particle size design, a 45S5 pure system formulation, and a dry grinding-airflow coupling preparation process. Compared to existing conventional bioactive glass dressings, it boasts advantages such as good powder dispersibility, excellent antibacterial and anti-mite effects, strong anti-inflammatory and healing-promoting capabilities, gentleness and non-irritation, and adaptability to multiple scenarios, effectively addressing the pain points of wound repair after minimally invasive cosmetic procedures. The dressing prepared using optimized process parameters (melting at 1250℃ for 2.5 hours, ball-to-particle ratio of 12:1, airflow pulverization pressure of 0.7MPa, classifying wheel speed of 2000 r / min, and bimodal particle size ratio of 65% / 35%) exhibits optimal overall performance, better meeting the rapid repair needs after minimally invasive cosmetic procedures, and possesses extremely high clinical application value and promising prospects for industrialization.

[0047] The above is a detailed description of the embodiments, which is intended to enable those skilled in the art to correctly understand and use the present invention. Any improvements or modifications to technical solutions obtained by those skilled in the art based on the present invention and on the existing technology, without innovative effort but only through analysis, analogy, or limited enumeration, should be within the scope of protection defined by the claims.

Claims

1. A bimodal bioactive glass wound dressing, characterized in that, The core raw material of the wound dressing is 45S5 bioactive glass powder, which is a pure system without added antibacterial agents or modifiers. The mass percentage composition of the 45S5 bioactive glass is: SiO2 45%, Na2O2 4.5%, CaO2 4.5%, P2O5 6%. The 45S5 bioactive glass powder has a dual-modal particle size distribution of 5-10μm, wherein the mass percentage of powder with a particle size of 5-7μm is 60%-70%, and the mass percentage of powder with a particle size of 7-10μm is 30%-40%.

2. The bimodal bioactive glass wound dressing according to claim 1, characterized in that, In the 45S5 bioactive glass powder, the powder with a particle size of 5-7μm accounts for 65% of the mass, and the powder with a particle size of 7-10μm accounts for 35% of the mass.

3. The bimodal bioactive glass wound dressing according to claim 1, characterized in that, The wound dressing also includes a compound solvent, which is physiological saline or hyaluronic acid, and the mass ratio of the 45S5 bioactive glass powder to the compound solvent is 15-25:75-85.

4. The bimodal bioactive glass wound dressing according to claim 3, characterized in that, The mass ratio of the 45S5 bioactive glass powder to the compound solvent is 20:

80.

5. A bimodal bioactive glass wound dressing as described in any one of claims 1-4 and its dry grinding-airflow coupling preparation method, characterized in that, Includes the following steps: (1) Precursor preparation: Weigh SiO2, Na2O, CaO, and P2O5 raw materials by mass percentage and mix them evenly. Melt them at 1200-1300℃ for 2-3 hours. After melting, cool to room temperature and crush to obtain block precursors. (2) Dry grinding and coarse crushing: Place the block precursors in a zirconia ball mill for anhydrous dry grinding. Control the ball-to-material mass ratio to be 10:1-15:1 and the rotation speed to be 300-400 r / min. Dry grind for 2-4 hours to obtain primary powder. (3) Dual-mode airflow pulverization: Feed the primary powders into a closed-loop airflow pulverizer. Control the pulverization pressure to be 0.6-0.8 MPa and the classifier rotation speed to be 1500-2500 r / min. r / min, combined with online particle size monitoring to adjust parameters in real time, to prepare powder with the 5-10μm dual-modal particle size distribution; (4) Multi-stage negative pressure sieving: the powder obtained in step (3) is sequentially sieved through 100 mesh and 200 mesh sieves under negative pressure, and the finished 45S5 bioactive glass powder is collected.

6. The preparation method according to claim 5, characterized in that, In step (1), the melting temperature is 1250℃ and the melting time is 2.5h.

7. The preparation method according to claim 5, characterized in that, In step (2), the conditions for dry grinding and coarse crushing are: ball-to-material mass ratio of 12:1, rotation speed of 350 r / min, and dry grinding time of 3h.

8. The preparation method according to claim 5, characterized in that, In step (3), the conditions for the dual-mode airflow pulverization are: pulverization pressure of 0.7 MPa and classifier speed of 2000 r / min.

9. The use of a bimodal bioactive glass wound dressing as described in any one of claims 1-4 in the preparation of products for postoperative wound repair in minimally invasive medical aesthetic procedures.

10. The application according to claim 9, characterized in that, The minimally invasive medical aesthetic procedures mentioned include those following laser treatments, photon skin rejuvenation, microdermabrasion, or chemical peels; the wound repair products are compatible with procedures including topical application, electrotherapy, needle-free mesotherapy, microneedling, or mesotherapy machine injection.

Images